Circio Holding ASA: Minutes from the annual general meeting 2026

Summary by AI ^BETAClose X

Circio Holding ASA held its annual general meeting on May 8, 2026, where all board proposals were approved, including the 2025 annual accounts and the appointment of KPMG as the new auditor. The meeting also saw the election of new board members. While no specific financial figures were disclosed in this announcement, the approval of annual accounts and auditor appointments are standard corporate governance procedures that confirm operational continuity.

Disclaimer*

Oslo, 8 May 2026: Circio Holding ASA (the “Company”) held its annual general meeting today. The meeting was held as a physical meeting at the premises of Advokatfirmaet Thommessen AS, Ruseløkkveien 38, 0251 Oslo, Norway.

All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2025 annual accounts, election of KPMG as the Company’s new auditor and election of members to the board of directors.

The minutes from the annual general meeting are attached hereto and will also be made available on the Company’s website circio.com/investors/general-meetings.

This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.